English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 13 March 2020, 18:00 HKT/SGT
Share:
    

Source: Agilex Biolabs
Agilex Biolabs Announces 30% Labs Expansion and Offers Virtual Lab Tours During COVID-19 Outbreak

ADELAIDE, AUS, Mar 13, 2020 - (ACN Newswire) - Award-winning Australian bioanalytical laboratory Agilex Biolabs announced today it has expanded its lab facilities by more than 30% to accommodate demand, mainly from US and APAC-based biotech companies.


As the only FDA-inspected lab of its type in the region, Agilex is located in Adelaide, South Australia, in a science and biotech specialist hub.

The company specialises in bioanalysis for small molecules and biologics for PK, immunogenicity and biomarkers utilising the two platforms of LC-MS/MS and Immunoassay (MesoScale, Gyrolab).

Agilex also offers pharmacodynamics services that include immunobiology services using the latest state-of-the-art technology to support immunology, cell biology and mode of action assays, including:
- Immunophenotyping
- Receptor occupancy
- Cytokine release assays (whole blood or PBMC stimulation assays) and cytokine / biomarker profiling
- PBMC assays and cellular mechanism of action assays (eg: ADCC)

Agilex Biolabs CEO Jason Valentine said they will now be offering virtual tours of the lab for customers who have travel restrictions during the current Covid-19 outbreak.

CEO Jason Valentine said:

"Our FDA-inspected facilities have more than 65 dedicated laboratory staff, and annually support more than 80 clinical trials. This year we will analyse more than 60,000 samples for pharma / biotechs from US, Europe and APAC.

"By combining specialised expertise, technological innovation and a 20-year track record, we have supported hundreds of preclinical and clinical trials around the world.

"Our world-class bioanalytical facilities have OECD GLP Recognition with NATA (Australian Government OECD GLP Compliance monitoring authority) and ISO 17025 Accreditation for global recognition."

Learn more:
- Watch the Agilex Biolabs video: https://youtu.be/3lyodiqqM_k
- Download the New Services data sheet: https://tinyurl.com/AgilexBiolabs

About Agilex Biolabs
Agilex Biolabs began as a group of academic scientists providing clinical trial and bioanalytical services to the local Australian pharmaceutical industry in the 1980's, and has now grown into a global business for early phase clinical trials. In our 20 years of performing regulated bioanalysis of small and large molecules, we have accelerated hundreds of preclinical and clinical trials around the world. Today, our clients include many of the leading pharmaceutical and biotechnology companies in Asia, Europe and the USA. Call +61 8 8302 8777 or +1 800 247 1909 or visit https://www.agilexbiolabs.com/.

Media Contact:
Team@DMGPR.Com
David James
AU: +61 2 8218 2144
USA: +1 415 951 3228
Asia: +65 3159 3427


Topic: Clinical Trial Results
Source: Agilex Biolabs

Sectors: BioTech, Healthcare & Pharm
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2022 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Agilex Biolabs Related News
2022年5月12日 16時00分 JST
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
May 12, 2022 15:00 HKT/SGT
Elevating Australia's Scientific Acumen: Large Molecule Facility Doubles Size of Australia's Top Bioanalytical Laboratory
Oct 19, 2021 15:00 HKT/SGT
Agilex Biolabs Shares How to Select the Right Bioanalytical Tools for Immuno-oncology and Vaccines Studies - OCT Webinar
Sept 24, 2021 17:00 HKT/SGT
애질렉스 바이오랩스, 사이트라인 어워드(Citeline Award)의 코로나19 백신 독성학 임상 전 연구 부문 최종 수상 후보로 선정
Sept 24, 2021 09:00 HKT/SGT
Agilex Biolabs Announced as Citeline Award Finalist for COVID-19 Vaccine Toxicology Preclinical Research
More news >>
Copyright © 2022 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575